ZA974331B - Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters - Google Patents

Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Info

Publication number: ZA974331B
Authority: ZA; South Africa
Prior art keywords: fatty acid; acid esters; aqueous suspensions; hydroxyrisperidone fatty; hydroxyrisperidone
Prior art date: 1996-05-20

Application number

ZA974331A

Other languages

English (en)

Inventor

Marc Karel Jozef Francois

Roger Carolus August Embrechts

Herman Karel Borghijs

Johan Monbaliu

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-20

Filing date

1997-05-19

Publication date

1998-11-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA974331(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-05-19 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1998-11-19 Publication of ZA974331B publication Critical patent/ZA974331B/xx

Links

-1 9-hydroxyrisperidone fatty acid esters Chemical class 0.000 title 1
239000007900 aqueous suspension Substances 0.000 title 1
235000014113 dietary fatty acids Nutrition 0.000 title 1
229930195729 fatty acid Natural products 0.000 title 1
239000000194 fatty acid Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

ZA974331A 1996-05-20 1997-05-19 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters ZA974331B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP96201429		1996-05-20

Publications (1)

Publication Number	Publication Date
ZA974331B true ZA974331B (en)	1998-11-19

Family

ID=8224016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA974331A ZA974331B (en)	1996-05-20	1997-05-19	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Country Status (37)

Country	Link
US (1)	US6077843A (pl)
EP (1)	EP0904081B1 (pl)
JP (1)	JP3274687B2 (pl)
KR (1)	KR100358373B1 (pl)
CN (1)	CN1093762C (pl)
AR (1)	AR007194A1 (pl)
AT (1)	ATE208619T1 (pl)
AU (1)	AU715572B2 (pl)
BG (1)	BG62684B1 (pl)
BR (1)	BR9706824B8 (pl)
CA (1)	CA2236691C (pl)
CY (2)	CY2270B1 (pl)
CZ (1)	CZ291284B6 (pl)
DE (2)	DE122011100027I1 (pl)
DK (1)	DK0904081T3 (pl)
EA (1)	EA000536B1 (pl)
EE (1)	EE03594B1 (pl)
ES (1)	ES2167745T3 (pl)
FR (1)	FR11C0035I2 (pl)
HR (1)	HRP970276B1 (pl)
HU (2)	HU224025B1 (pl)
ID (1)	ID16927A (pl)
IL (1)	IL124551A (pl)
LU (1)	LU91842I2 (pl)
MX (1)	MX9804816A (pl)
MY (1)	MY126302A (pl)
NO (2)	NO315931B1 (pl)
NZ (1)	NZ330369A (pl)
PL (1)	PL188309B1 (pl)
PT (1)	PT904081E (pl)
SI (1)	SI0904081T1 (pl)
SK (1)	SK284013B6 (pl)
TR (1)	TR199800923T2 (pl)
TW (1)	TW487572B (pl)
UA (1)	UA61898C2 (pl)
WO (1)	WO1997044039A1 (pl)
ZA (1)	ZA974331B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA72189C2 (uk)	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP2002504505A (ja) *	1998-02-25	2002-02-12	アボット・ラボラトリーズ	ブトルファノール持続放出性製剤
US6342488B1 (en)	1998-08-18	2002-01-29	Sepracor, Inc.	Phosphonorisperidone and sulforisperidone compositions and methods
MX339071B (es)	1999-03-31	2016-05-09	Janssen Pharmaceutica Nv	Almidon pregelatinizado en una formulacion de liberacion controlada.
US6495164B1 (en) *	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
ATE401313T1 (de) *	2000-08-14	2008-08-15	Teva Pharma	Herstellung von risperidon
US7666445B2 (en) *	2000-10-20	2010-02-23	The Trustees Of The University Of Pennsylvania	Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) *	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
JP4500679B2 (ja) *	2002-07-29	2010-07-14	アルザ・コーポレーシヨン	パリペリドンを制御送達する方法および投薬形態物
US20050232995A1 (en)	2002-07-29	2005-10-20	Yam Nyomi V	Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0322994D0 (en) *	2003-10-01	2003-11-05	Novartis Ag	Organic compounds
BRPI0415531B8 (pt)	2003-10-23	2021-05-25	Otsuka Pharma Co Ltd	formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
KR101242486B1 (ko) *	2004-01-12	2013-03-13	더 트러스티스 오브 더 유니버시티 오브 펜실베니아	장기 전달을 위한 제형 및 그의 이용 방법
US8329203B2 (en) *	2004-01-12	2012-12-11	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
US8221778B2 (en)	2005-01-12	2012-07-17	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
ES2245252B1 (es) *	2004-06-15	2007-03-01	Farmalider, S.A.	Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
CN101163702B (zh)	2005-04-25	2011-09-07	詹森药业有限公司	制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
PL116330U1 (en)	2005-10-31	2007-04-02	Alza Corp	Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
PL2359808T3 (pl)	2006-08-09	2013-10-31	Intarcia Therapeutics Inc	Osmotyczne systemy dostawcze i zespoły tłokowe
US8314110B2 (en) *	2007-04-19	2012-11-20	Youxin Li	Compounds for treating mental disorders, and preparation and uses thereof
EP2157967B1 (en)	2007-04-23	2013-01-16	Intarcia Therapeutics, Inc	Suspension formulations of insulinotropic peptides and uses thereof
US20090076035A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched paliperidone
CA2655335C (en) *	2007-12-19	2016-09-06	Janssen Pharmaceutica N.V.	Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US20090209757A1 (en) *	2008-01-10	2009-08-20	Santiago Ini	Processes for the preparation and purification of paliperidone palmitate
EP2240155B1 (en)	2008-02-13	2012-06-06	Intarcia Therapeutics, Inc	Devices, formulations, and methods for delivery of multiple beneficial agents
EP3685837A1 (en)	2008-09-04	2020-07-29	Amylin Pharmaceuticals, LLC	Sustained release formulations using non-aqueous carriers
EP3323423B1 (en)	2009-09-28	2020-06-17	Intarcia Therapeutics, Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
AU2010313290A1 (en)	2009-10-30	2012-05-17	Janssen Pharmaceutica Nv	Dosing regimen associated with long-acting injectable paliperidone esters
US20120259116A1 (en) *	2009-12-17	2012-10-11	Rajiv Kumar	Novel Process for the Preparation of Paliperidone
TWI577377B (zh)	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
US9469630B2 (en)	2010-10-18	2016-10-18	Sumitomo Dainippon Pharma Co., Ltd.	Sustained-release formulation for injection
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ES2587527T3 (es) *	2011-05-31	2016-10-25	RAMAMOHAN RAO, Davuluri	Preparación de 3-[2-[4-((6-fluoro-1,2-bencisoxazol-3-il)-l-piperidinil)-6,7,8,9-tetrahidro-9-hidroxi-2-metil-4H-pirido[1,2 a]-primidin-4-ona (paliperidona) y palmitato de paliperidona
WO2013046225A2 (en) *	2011-08-10	2013-04-04	Glenmark Generics Limited	Process for the preparation of paliperidone palmitate
CN102993200B (zh) *	2011-09-10	2016-02-03	鲁翠涛	帕潘立酮氨基酸酯及其制备方法
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
DK3744326T3 (da)	2015-04-07	2024-02-05	Janssen Pharmaceutica Nv	Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
ES2968262T3 (es)	2015-06-03	2024-05-08	I2O Therapeutics Inc	Sistemas de colocación de implantes
KR20240037175A (ko)	2016-05-16	2024-03-21	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
AU2018206539A1 (en)	2017-01-03	2019-07-18	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
SI4025187T1 (sl)	2020-11-30	2024-03-29	Janssen Pharmaceutica Nv	Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh)	2020-11-30	2023-08-01	詹森药业有限公司	与延长释放帕潘立酮可注射制剂相关的给药方案
EP4025188B1 (en)	2020-11-30	2024-01-10	Janssen Pharmaceutica NV	Dosing regimens associated with extended release paliperidone injectable formulations
PL4005555T3 (pl)	2020-11-30	2024-09-02	Janssen Pharmaceutica Nv	Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
HUP2100259A1 (hu)	2021-07-07	2023-01-28	Richter Gedeon Nyrt	Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
MX2024002215A (es)	2021-08-20	2024-05-10	Janssen Pharmaceutica Nv	Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2000786C (en) *	1988-11-07	1999-01-26	Janssen Pharmaceutica, Naamloze Vennootschap	3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) *	1988-11-07	1992-10-27	Janssen Pharmaceutica N.V.	3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) *	1988-11-07	1993-10-19	Janssen Pharmaceutica N.V.	3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) *	1993-04-28	1999-12-11	Janssen Pharmaceutica Nv	Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ATE288270T1 (de) *	1993-11-19	2005-02-15	Janssen Pharmaceutica Nv	Mikroverkapselte 1,2-benzazole
US5650173A (en) *	1993-11-19	1997-07-22	Alkermes Controlled Therapeutics Inc. Ii	Preparation of biodegradable microparticles containing a biologically active agent
ATE212830T1 (de) *	1993-11-19	2002-02-15	Alkermes Inc	Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
ES2157442T3 (es) *	1995-06-06	2001-08-16	Aventis Pharma Inc	Derivados de benzoisoxazol y de indazol, utilizados como agentes neurolepticos.
US5792477A (en) *	1996-05-07	1998-08-11	Alkermes Controlled Therapeutics, Inc. Ii	Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

1997
- 1997-05-01 TW TW086105768A patent/TW487572B/zh not_active IP Right Cessation
- 1997-05-12 AT AT97923912T patent/ATE208619T1/de active
- 1997-05-12 BR BRPI9706824-1B8A patent/BR9706824B8/pt not_active IP Right Cessation
- 1997-05-12 DE DE201112100027 patent/DE122011100027I1/de active Pending
- 1997-05-12 KR KR10-1998-0703629A patent/KR100358373B1/ko not_active Expired - Lifetime
- 1997-05-12 SI SI9730272T patent/SI0904081T1/xx unknown
- 1997-05-12 HU HU9901319A patent/HU224025B1/hu active Protection Beyond IP Right Term
- 1997-05-12 DK DK97923912T patent/DK0904081T3/da active
- 1997-05-12 TR TR1998/00923T patent/TR199800923T2/xx unknown
- 1997-05-12 JP JP54150097A patent/JP3274687B2/ja not_active Expired - Lifetime
- 1997-05-12 PT PT97923912T patent/PT904081E/pt unknown
- 1997-05-12 NZ NZ330369A patent/NZ330369A/xx not_active IP Right Cessation
- 1997-05-12 CZ CZ19981401A patent/CZ291284B6/cs not_active IP Right Cessation
- 1997-05-12 ES ES97923912T patent/ES2167745T3/es not_active Expired - Lifetime
- 1997-05-12 CA CA002236691A patent/CA2236691C/en not_active Expired - Lifetime
- 1997-05-12 EA EA199800531A patent/EA000536B1/ru not_active IP Right Cessation
- 1997-05-12 EE EE9800136A patent/EE03594B1/xx active Protection Beyond IP Right Term
- 1997-05-12 US US09/180,659 patent/US6077843A/en not_active Expired - Lifetime
- 1997-05-12 WO PCT/EP1997/002504 patent/WO1997044039A1/en not_active Ceased
- 1997-05-12 EP EP97923912A patent/EP0904081B1/en not_active Expired - Lifetime
- 1997-05-12 CN CN97191494A patent/CN1093762C/zh not_active Expired - Lifetime
- 1997-05-12 DE DE69708284T patent/DE69708284T2/de not_active Expired - Lifetime
- 1997-05-12 IL IL12455197A patent/IL124551A/xx not_active IP Right Cessation
- 1997-05-12 SK SK620-98A patent/SK284013B6/sk not_active IP Right Cessation
- 1997-05-12 PL PL97327995A patent/PL188309B1/pl unknown
- 1997-05-12 AU AU29559/97A patent/AU715572B2/en not_active Expired
- 1997-05-19 ZA ZA974331A patent/ZA974331B/xx unknown
- 1997-05-19 MY MYPI97002172A patent/MY126302A/en unknown
- 1997-05-19 AR ARP970102112A patent/AR007194A1/es active IP Right Grant
- 1997-05-19 ID IDP971649A patent/ID16927A/id unknown
- 1997-05-20 HR HR970276A patent/HRP970276B1/xx not_active IP Right Cessation
- 1997-12-05 UA UA98052747A patent/UA61898C2/uk unknown
1998
- 1998-04-30 NO NO19981984A patent/NO315931B1/no not_active IP Right Cessation
- 1998-05-12 BG BG102443A patent/BG62684B1/bg unknown
- 1998-06-15 MX MX9804816A patent/MX9804816A/es unknown
2002
- 2002-04-25 CY CY0200021A patent/CY2270B1/xx unknown
2011
- 2011-07-20 LU LU91842C patent/LU91842I2/fr unknown
- 2011-08-18 HU HUS1100013C patent/HUS1100013I1/hu unknown
- 2011-08-18 CY CY2011011C patent/CY2011011I1/el unknown
- 2011-08-29 NO NO2011015C patent/NO2011015I2/no unknown
- 2011-09-02 FR FR11C0035C patent/FR11C0035I2/fr active Active

Also Published As

Publication number	Publication date
FR11C0035I1 (pl)	2011-07-10
CY2270B1 (en)	2003-07-04
NO2011015I1 (no)	2011-09-19
DE122011100027I1 (de)	2011-11-17
HUP9901319A3 (en)	1999-11-29
CY2011011I2 (el)	2016-12-14
ID16927A (id)	1997-11-20
EP0904081B1 (en)	2001-11-14
UA61898C2 (en)	2003-12-15
EE03594B1 (et)	2002-02-15
DE69708284T2 (de)	2002-07-25
NO2011015I2 (no)	2013-03-11
SK284013B6 (sk)	2004-08-03
BG102443A (en)	1999-06-30
LU91842I2 (fr)	2011-09-20
EP0904081A1 (en)	1999-03-31
JP3274687B2 (ja)	2002-04-15
HK1017852A1 (en)	1999-12-03
AU715572B2 (en)	2000-02-03
MX9804816A (es)	1998-10-31
FR11C0035I2 (fr)	2013-08-16
DE69708284D1 (de)	2001-12-20
HU224025B1 (hu)	2005-05-30
KR19990067603A (ko)	1999-08-25
US6077843A (en)	2000-06-20
AU2955997A (en)	1997-12-09
HRP970276A2 (en)	1998-04-30
CY2011011I1 (el)	2016-12-14
SK62098A3 (en)	2000-04-10
IL124551A0 (en)	1998-12-06
AR007194A1 (es)	1999-10-13
HUS1100013I1 (hu)	2017-03-28
BG62684B1 (bg)	2000-05-31
CN1206347A (zh)	1999-01-27
BR9706824A (pt)	1999-03-23
WO1997044039A1 (en)	1997-11-27
PT904081E (pt)	2002-04-29
NO315931B1 (no)	2003-11-17
PL188309B1 (pl)	2005-01-31
NO981984L (no)	1998-11-19
DK0904081T3 (da)	2002-02-25
CA2236691A1 (en)	1997-11-27
PL327995A1 (en)	1999-01-04
TR199800923T2 (xx)	1999-09-21
ATE208619T1 (de)	2001-11-15
CN1093762C (zh)	2002-11-06
JP2000513718A (ja)	2000-10-17
NO981984D0 (no)	1998-04-30
CZ140198A3 (cs)	1999-04-14
CA2236691C (en)	2007-01-02
HUP9901319A2 (hu)	1999-08-30
IL124551A (en)	2001-08-26
EE9800136A (et)	1998-10-15
MY126302A (en)	2006-09-29
BR9706824B8 (pt)	2015-02-18
NZ330369A (en)	2000-04-28
SI0904081T1 (en)	2002-04-30
TW487572B (en)	2002-05-21
EA000536B1 (ru)	1999-10-28
CZ291284B6 (cs)	2003-01-15
EA199800531A1 (ru)	1998-12-24
HRP970276B1 (en)	2002-04-30
ES2167745T3 (es)	2002-05-16
KR100358373B1 (ko)	2003-02-11

Publication	Publication Date	Title
CY2270B1 (en)	2003-07-04	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
HUP0100155A3 (en)	2006-07-28	Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
PL331700A1 (en)	1999-08-02	Method of obtaining fatty acid esters
GB9403857D0 (en)	1994-04-20	Fatty acid derivatives
GB9508023D0 (en)	1995-06-07	Fatty acid derivatives
IL115594A0 (en)	1996-01-19	Preparation of alpha-tertiary carboxylic acid esters
HUP0103334A3 (en)	2003-05-28	Substituted cinnamic acids and cinnamic acid esters
IL122919A0 (en)	1998-08-16	Preparation of 1-alkyl-pyrazole-5-carboxylic acid esters
IL123213A0 (en)	1998-09-24	Carboxylic acid derivatives
GB9517107D0 (en)	1995-10-25	Fatty acid esters
GB2312208B (en)	2000-01-19	Preparation of carboxylic acids from alcohols
SG28202A1 (en)	1996-04-01	Fatty acid derivatives
ZA9586B (en)	1995-07-20	New sulfuric acid esters of sugar alochols
HUP9902844A3 (en)	2003-02-28	Manufacture of fatty acid esters of sorbitan as surfactants